Table 3.

a: Demographic and step count data, b: Correlation and regression statistics for daily step count and clinic-based performance measures and patient-reported outcomes

Demographic data		Entire cohort	Progressive MS	Relapsing MS
a
Total N (% of cohort)		99	38 (38%)	61 (62%)
Women (% of MS subtype)		63 (64%)	20 (53%)	43 (71%)
Men (% of MS subtype)		36 (36%)	18 (47%)	18 (29%)
Age (years)
Mean (SD)		50.1 (13.8)	57.7 (9.1)	45.4 (14.2)
Disease duration (years)
Median (interquartile range 25–75%)		13.0 (6.0–21.0)	16.0 (9.0–21.0)	9.0 (4.0–21.0)
EDSS
Mean (range)		4.1 (0.0–6.5)	5.5 (3.0–6.5)	3.2 (0.0–6.5)
Steps per day
Average (SD)		5478 (3507)	3809 (2104)	6477 (3707)
Minimum–maximumA		533–18,649	533–8396	1129–18,649
RangeB		326–28,074	326–15,118	336–28,074
Correlation and regressionstatistics	Outcomemeasure	Univariate model:Spearman's q	Multivariate model: adjusted R2, (e)
b
Clinic-based	T25FW	−0.66d	0.38d
	TUG	−0.68d	0.40d
	2MW	0.69d	0.43d
Patient-reported	MSWS-12	−0.66d	0.37d
	MFIS-5	−0.41c	0.17c
	PES	−0.32c	0.09b
	BLCS	−0.39b	0.10a
	BWCS	−0.22a	0.07a
	MHI-5	−0.02a	−0.01a

In general, clinic-based performance measures displayed greater correlations with step count than patient-reported symptomatic outcomes, even in adjusted analyses. Significance, p values:

^anot statistically significant

^bp = 0.05

^cp 0.01

^dp 0.001

^egeneralized linear model: adjusting for age, sex, disease subtype

MS multiple sclerosis, SD standard deviation, EDSS Kurtzke Expanded Disability Status Scale, T25FW timed 25-foot walk, TUG timed up and go, 2MW 2-minute walk, MSWS-12 12-item MS Walking Scale, MFIS-5 Modified Fatigue Index (5 item version), PES Pain Effects Scale, BLCS Bladder Control Scale, BWCS Bowel Control Scale, MHI-5 Mental Health Inventory (5 item version)

^AAverage steps per day, over 4 weeks

^BTotal steps per day, per participant